



Resource impact template

Resource impact

Published: 18 June 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for untreated extensive-stage small-cell lung cancer:

- [Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer](#) (2026) NICE technology appraisal guidance 1167
- [Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer](#) (2025) NICE technology appraisal guidance 1041
- [Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer](#) (2020) NICE technology appraisal guidance 638